Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...

The global Therapeutic Plasma Exchange Market, valued at US$ 1.5 billion in 2022, is projected to grow at a compound annual ...

getting the go-ahead in December 2021 for generalised myasthenia gravis (gMG). Vyvgart Hytrulo was cleared for gMG in the US a year ago, and Argenx chose to use a priority review voucher (PRV ...

Amicus™ high collection efficiency yields multiple products per donor for the lowest-cost platelet production. It is designed to adapt to the requirements of different collection settings. Let ...

Multiple myeloma is part of the spectrum of diseases ranging from MGUS to plasma cell leukemia, and similar to MGUS, is characterized by proliferation of a plasma cell clone and subsequent ...